Full-Time

Senior Director

Clinical Operations

City Therapeutics

City Therapeutics

51-200 employees

Develops RNAi therapeutics using trigger molecules

Compensation Overview

$253.3k - $286.7k/yr

+ Bonus + Equity

Cambridge, MA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Risk Management
Data Analysis
Requirements
  • Bachelor’s degree in a scientific discipline required; advanced degree preferred
  • Minimum 12 years in biotech/pharma/CRO settings
  • At least 10 years in clinical operations
  • Minimum 5 years in a supervisory role
  • Proven track record of managing complex drug development trials
  • Demonstrated leadership through vision, mentorship, and organizational development
  • Highly organized, outcome-oriented, and self-motivated
  • Adaptable to fast-paced environments
  • Deep expertise in clinical operations and program management
  • Strong interpersonal, conflict resolution, and negotiation skills
  • Analytical thinker with strategic planning capabilities
  • Excellent knowledge of federal regulatory requirements and Good Clinical Practice guidelines
  • Exceptional oral and written communication skills
Responsibilities
  • Program Oversight: Clinical operations leadership across assigned programs, including trial management, site monitoring, vendor selection and oversight, Trial Master File, data operations, timeline and budget adherence
  • Document Development: Collaborate with cross-functional teams to contribute to protocols, project plans, timelines, statistical analysis plans, and final study reports
  • Compliance & Quality: Ensure adherence to Standard Operating Procedures and Good Clinical Practice/International Conference on Harmonisation guidelines; maintain inspection readiness throughout the trial lifecycle
  • Risk Management: Proactively identify, resolve, and escalate issues that could impact timelines or budgets
  • Country and Site Strategy: Identify, evaluate, and recruit clinical trial locations and sites globally
  • Regulatory Support: Contribute to global clinical and regulatory submissions
  • Stakeholder Engagement: Serve as a subject matter expert, educating and engaging stakeholders to enhance organizational effectiveness
  • Team Leadership: Provide line management, coaching, and mentorship to assigned team members, as well as represent clinical operations in various cross functional forums (Program team, sub-teams, etc)
  • Process Improvement: Support the development and refinement of departmental Standard Operating Procedures and work instructions, streamline ways of working and create efficiencies throughout the lifecycle of clinical trials
  • Travel: May require domestic and international travel
Desired Qualifications
  • Advanced degree (e.g., Master’s or Doctorate) in a scientific discipline
  • Experience leading global cross-functional teams across multiple therapeutic areas
  • Proven track record of successful regulatory submissions and inspections
  • Experience with health economics and outcomes research is a plus
  • Experience with electronic trial master file systems and data management platforms

City Therapeutics develops RNA interference (RNAi) medicines. It works on creating next-generation trigger molecules and delivery ligands to silence disease-causing genes in the body. The core product approach uses RNAi to turn off specific genes in cells, reducing the production of harmful proteins. Delivery and targeting are tailored, so the RNAi triggers reach the right tissues more effectively than before. Compared with peers, City Therapeutics emphasizes proprietary trigger chemistry and ligand-based delivery to improve precision and expand the range of diseases that can be treated, aiming for strong therapeutic impact rather than relying on traditional small molecules or antibodies. The company’s goal is to advance and apply RNAi-based medicines across multiple conditions by leveraging human genetics insights, partnerships, and focused development to bring effective gene-silencing therapies to patients.

Company Size

51-200

Company Stage

Series A

Total Funding

$135M

Headquarters

Massachusetts

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • Biogen CNS partnership yields $16M upfront and $1B milestones.
  • CITY-FXI Phase 1 trial yields data late 2026 for thromboembolism.
  • $135M Series A funds pipeline through 2026 IND cadence.

What critics are saying

  • Alnylam erodes edge with superior GalNAc siRNAs in 12-24 months.
  • Silence SLN360 Phase 2 captures Factor XI market in 18-24 months.
  • Cash burns $135M by mid-2027 without Series B funding.

What makes City Therapeutics unique

  • Next-generation cityRNA triggers enable extra-hepatic tissue targeting beyond liver.
  • Co-founded by Alnylam veterans like John Maraganore for RNAi expertise.
  • Proprietary siRNA engineering expands RNAi to CNS and rare diseases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

Flexible Work Hours

Remote Work Options

Hybrid Work Options

Life Insurance

Disability Insurance

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Family Planning Benefits

Fertility Treatment Support

Stock Options

Company Equity

Company News

Business Wire
Oct 8th, 2024
City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine

City Therapeutics launches with $135M to lead the future of RNAi-based medicine; led by founding Alnylam CEO and RNAi pioneer Dr. John Maraganore